FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined …
WEBMay 5, 2021 · KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS ≥10) as …
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
WEB3 days ago · RAHWAY, N.J., September 18, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck ...
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
WEBNov 16, 2023 · Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone. Approval marks seventh gastrointestinal cancer indication for KEYTRUDA-based regimens and 38th indication for KEYTRUDA in the US.
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy …
WEBApr 16, 2023 · RAHWAY, N.J.-- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-966 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with standard of care chemotherapy (gemcitabine and cisplatin) for the first-line treatment of patients with advance...
Merck's Keytruda Secures First FDA-Approval For Rare Form …
WEB2 days ago · Wednesday, the FDA approved Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with ...
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) …
WEB5 days ago · RAHWAY, N.J., September 15, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data from the pivotal Phase 3 KEYNOTE-006 ...
Merck wins first FDA approval for Keytruda as a treatment for ...
WEB3 days ago · Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...
FDA Grants Priority Review to Merck's Application for KEYTRUDA ...
WEBFeb 20, 2024 · Results showed KEYTRUDA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus chemotherapy in these patients, regardless of mismatch repair status.
Merck Gets European Panel Backing for Keytruda in Two …
WEB22 hours ago · Sep 20, 2024 5:06am. By Colin Kellaher. Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of ...
FDA approves pembrolizumab as adjuvant treatment for non …
WEBOn January 26, 2023, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a...
Skip to content